leronlimab + penpulimab + gemcitabine + carboplatin

leronlimab + penpulimab + gemcitabine + carboplatin is an investigational combination regimen being evaluated for the treatment of metastatic triple-negative breast cancer (mTNBC). The regimen combines leronlimab (PRO 140), a humanized monoclonal antibody targeting the CCR5 receptor, with penpulimab (AK105), an anti-PD-1 monoclonal antibody, and the standard chemotherapy agents gemcitabine and carboplatin. This combination is being studied in the Phase 1-1b PRE7 trial, sponsored by the Quantum Leap Healthcare Collaborative (QLHC) as part of the PRE-I-SPY platform. The regimen is designed to evaluate whether CCR5 inhibition can modulate the tumor microenvironment and enhance the efficacy of immunotherapy and chemotherapy in patients with mTNBC, particularly those with low PD-L1 expression.